| Formulary Chapter 9: Nutrition and blood - Full Chapter
|
| Chapter Links... |
 County Durham and Tees Valley Guidelines for recognition and management of non- IgE cow’s milk allergy in children |
| Guidance for the Prescribing of Vitamins and Minerals in Primary Care in County Durham and Tees Valley |
 North of Tyne, Gateshead and North Cumbria - Recommendations for symptom management in renal patients (including symptom management at the end of life) |
| South Tees Pathway for the Management of Undernutrition (ADULTS) |
| South Tees Pathway for the Management of Undernutrition (Nursing/Care Homes) |
| Details... |
| 09.02.02 |
Parenteral preparations for fluid and electrolyte imbalance |
|
|
Steriflex 165®
|
Formulary
|
- Potassium chloride 0.3% (20mmol); sodium chloride 0.9%; and glucose 5% (500ml bag).
- Approved for diabetic ketoacidosis in paediatric patients
 unlicensed.
|
|
|
Trometamol (THAM)
|
Formulary
|
|
|
|
| 09.02.02.01 |
Electrolytes and water |
|
|
Hartmann’s solution (compound sodium lactate)
|
Formulary
|
|
|
|
Water for Injection (Viaflo® - FE0304)
|
Formulary
|
- Approved for use by the North-East Assisted Ventilation Service (NEAVS)
- to be prescribed in boxes of 10
|
|
|
| 09.02.02.01 |
Intravenous sodium |
|
|
Sodium Chloride
|
Formulary
|
- 0.9% injection (5ml, 10ml & 20ml)
- 0.9% IV infusion (100ml, 250ml, 500ml & 1000ml)
- 0.9% irrigation (1000ml & 3000ml)
- 0.45% IV infusion (500ml - Steriflex 2)
- 1.8%, 2.7% & 5% Polyfusor infusion (500ml)
- 30% injection (10ml)
|
|
|
Sodium Chloride and Glucose
|
Formulary
|
- 0.9%/5% IV infusion (500ml - Sterfilex 3)
- 0.18%/4% IV infusion (500ml & 1000ml)
- 0.18%/10% IV infusion (500ml - Steriflex 19)
- 0.45%/5% IV infusion (500ml - Steriflex 45)
|
|
|
| 09.02.02.01 |
Intravenous glucose |
|
|
Glucose
|
Formulary
|
- 5% IV infusion (100ml, 250ml, 500ml & 1000ml)
- 10% IV infusion (500ml & 1000ml)
- 20% IV infusion (500ml)
- 50% Injection (50ml)
|
MHRA: Glucose solutions: recommendations to minimise the risks associated with the accidental use of glucose solutions instead of saline solutions in arterial lines (May 2023)
|
| 09.02.02.01 |
Intravenous potassium |
|
|
Premixed potassium infusion bags
|
Formulary
|
Infusion: 0.15% (10 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 5% glucose 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 10% glucose 500ml
Infusion: 0.15% (10 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.15% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion: 0.15% (10 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml
Infusion: 0.2% (13.5 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.2% (27 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.2% (13.5 mmol) potassium chloride & 5% glucose 500ml
Infusion: 0.2% (27 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.2% (13.5 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.2% (27 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.3% (40 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 5% glucose 500ml
Infusion: 0.3% (40 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 10% glucose 500ml
Infusion: 0.3% (20 mmol) potassium chloride & 20% glucose 500ml
Infusion: 0.3% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.3% (40 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion: 0.3% (20 mmol) potassium chloride, 0.45% sodium chloride & 5% glucose 500ml
Infusion: 0.3% (20 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml
Infusion: 0.6% (40 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.6% (40 mmol) potassium chloride & 5% glucose 500ml
|
|
|
| 09.02.02.01 |
Bicarbonate and lactate |
|
|
Sodium Bicarbonate
|
Formulary
|
- 1.26% IV infusion Polyfusor®
- 1.4% IV infusion Polyfusor®
- 2.74% IV infusion Polyfusor®
- 8.4% IV infusion Polyfusor®
- 8.4% injection (10ml & 50ml)
|
|
|
Sodium Lactate IV infusion
|
Formulary
|
|
|
|
| 09.02.02.01 |
Water |
|
|
Water for Injection
|
Formulary
|
- 2ml, 5ml, 10ml, 20ml, 100ml & 500ml
|
|
|
Water for Irrigation
|
Formulary
|
|
|
|
Sterile oral water
|
Formulary
|
|
|
|
| 09.02.02.02 |
Plasma and plasma substitutes |
|
|
Human Albumin Solution
|
Formulary
|
- 4.5% (50ml, 100ml & 500ml)
- 20% (50ml & 100ml)
|
|
|
Plasma-lyte 148 with Glucose 5%
|
Formulary
|
- Infusion in a balanced electrolyte solution containing Na+ 140 mmol, K+ 5 mmol, Mg2+ 1.5 mmol, acetate 27 mmol/litre. Gluconate 23 mmol/litre. Note calcium free.
- Approved for use in paediatric theatres only.
|
|
|
| 09.02.02.02 |
Plasma substitutes |
|
|
Dextran 40/Sodium Chloride
|
Formulary
|
|
|
|
Gelatin (Isoplex®)
|
Formulary
|
- 4%succinylated gelatin infusion in a balanced electrolyte solution containing Na+ 145 mmol, K+ 4 mmol, Mg2+ 0.9 mmol, Cl- 105 mmol, lactate 25 mmol/litre.
- Mainly for use in critical care areas and other situations where the perceived advantages of a balanced electrolyte plasma substitute are likely to be clinically important. Note Not yet cleared for use in NUTH.
|
|
|
Gelatin (Volplex® or Gelofusine®)
|
Formulary
|
- 4% succinylated gelatin infusion in sodium chloride 0.9% (500ml bags)
|
|
|
Tetrastarch (Tetraspan®)
|
Formulary
|
- 6% & 10% tetrastarch infusions in a balanced electrolyte solution containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 1 mmol, Cl- 118 mmol, Ca2+ 2.5 mmol, acetate 24 mmol, malate 5 mmol/litre.
Contains calcium
|
|
|
Tetrastarch (Volulyte®)
|
Formulary
|
- 6% tetrastarch infusion in a balanced electrolyte solution containing Na+ 137 mmol, K+ 4 mmol, Mg2+ 1.5 mmol, Cl110 mmol, acetate 34 mmol/litre.
Contains calcium.
- Mainly for use in indications where calcium containing fluids are unsuitable
|
|
|
Phoxilium 1.2mmol/l phosphate
|
 Restricted
|
- A haemofiltration and haemodialysis fluid containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 0.6 mmol, Ca2+ 1.25mmol/l, Cl- 115.9 mmol/l, HCO3 - 30.0mmol/l, HPO4 2- 1.20mmol/l.
- Approved for use in CRRT in patients not requiring reduced potassium or low bicarbonate.
|
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment.
In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.
For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing. |
|
Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement.
The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber.
If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care. |
|
Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs. |
|
Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care. |
|
NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria. |
|
UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review. |
|
NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status. |
|
|
|
